0000000000140991

AUTHOR

Serra C.

showing 6 related works from this author

Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma.

2014

Lead-time is the time by which diagnosis is anticipated by screening/surveillance with respect to the symptomatic detection of a disease. Any screening program, including surveillance for hepatocellular carcinoma (HCC), is subject to lead-time bias. Data regarding lead-time for HCC are lacking. Aims of the present study were to calculate lead-time and to assess its impact on the benefit obtainable from the surveillance of cirrhotic patients. Background & Aims: Lead-time is the time by which diagnosis is anticipated by screening/surveillance with respect to the symptomatic detection of a disease. Any screening program, including surveillance for hepatocellular carcinoma (HCC), is subject to …

Malemedicine.medical_specialtyPediatricsCarcinoma HepatocellularTime FactorsHepatocellular carcinomaSettore MED/12 - GASTROENTEROLOGIADiseaseGastroenterologyBiasInternal medicineOverall survivalmedicineHumansEarly Detection of CancerAgedEstimationSurveillanceHepatologybusiness.industryLiver Neoplasmsmedicine.diseasedigestive system diseasesLead time biasCirrhosisHepatocellular carcinomaFemalebusinessLead-time biasFollow-Up Studies
researchProduct

Portal Vein Thrombosis Relevance on Liver Cirrhosis: Italian Venous Thrombotic Events Registry

2016

Portal vein thrombosis may occur in cirrhosis; nevertheless, its prevalence, and predictors are still elusive. To investigate this issue, the Italian Society of Internal Medicine undertook the “Portal vein thrombosis Relevance On Liver cirrhosis: Italian Venous thrombotic Events Registry” (PRO-LIVER). This prospective multicenter study includes consecutive cirrhotic patients undergoing Doppler ultrasound examination of the portal area to evaluate the prevalence and incidence of portal vein thrombosis over a 2-year scheduled follow-up. Seven hundred and fifty-three (68 % men; 64 ± 12 years) patients were included in the present analysis. Fifty percent of the cases were cirrhotic outpatients.…

RegistrieLiver CirrhosisMaleCirrhosisHepatocellular carcinoma030204 cardiovascular system & hematologyGastroenterology0302 clinical medicineEsophageal varicesPrevalenceMedicineProspective StudiesRegistriesProspective cohort studyMultivariate AnalysiVenous ThrombosisPortal VeinAnticoagulants; Esophageal varices; Hepatocellular carcinoma; Liver failure; Splanchnic venous thrombosis; Emergency Medicine; Internal MedicineMiddle AgedPortal vein thrombosisVenous thrombosisSplanchnic venous thrombosis Anticoagulants Liver failure Hepatocellular carcinoma Esophageal varicesSplanchnic venous thrombosisItalyLiverEmergency MedicineFemale030211 gastroenterology & hepatologymedicine.symptomSettore SECS-S/01 - StatisticaHumanmedicine.medical_specialtyLiver CirrhosiSocio-culturaleEsophageal varicesAsymptomatic03 medical and health sciencesAnticoagulants Esophageal varices Hepatocellular carcinoma Liver failure Splanchnic venous thrombosisInternal medicineInternal MedicineHumansAgedHepatologyEsophageal varicebusiness.industryAnticoagulantLiver failureAnticoagulants; Esophageal varices; Hepatocellular carcinoma; Liver failure; Splanchnic venous thrombosis;AnticoagulantsSplanchnic venous thrombosimedicine.diseaseSurgeryProspective StudieSplanchnic venous thrombosis Anticoagulants Liver failure Hepatocellular carcinoma Esophageal varicesMultivariate AnalysisUpper gastrointestinal bleedingComplicationbusinessJournal of Hepatology
researchProduct

Death in hospital following ICU discharge: insights from the LUNG SAFE study

2021

Abstract Background To determine the frequency of, and factors associated with, death in hospital following ICU discharge to the ward. Methods The Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE study was an international, multicenter, prospective cohort study of patients with severe respiratory failure, conducted across 459 ICUs from 50 countries globally. This study aimed to understand the frequency and factors associated with death in hospital in patients who survived their ICU stay. We examined outcomes in the subpopulation discharged with no limitations of life sustaining treatments (‘treatment limitations’), and the subpopulations with tre…

MaleARDSLUNG SAFEhealth care facilities manpower and servicesAcute hypoxemic respiratory failure; Acute respiratory distress syndrome; Hospital survival; ICU discharge; LUNG SAFEKaplan-Meier EstimateCritical Care and Intensive Care MedicineAcute hypoxemic respiratory failure; Acute respiratory distress syndrome; Hospital survival; ICU discharge; LUNG SAFE;0302 clinical medicineRisk Factors030212 general & internal medicineProspective StudiesProspective cohort studyAcute hypoxemic respiratory failureCOPDAcute respiratory distress syndromeICU dischargeMedical emergencies. Critical care. Intensive care. First aidMiddle AgedPatient DischargeLUNG SAFE.Intensive Care Unitsmedicine.anatomical_structureLung safeSOFA scoreFemaleRespiratory InsufficiencyAdultmedicine.medical_specialtyNOHospital survival03 medical and health sciencesSettore MED/41 - ANESTESIOLOGIAmedicineHumansddc:610Risk factorMortalityAgedLungRC86-88.9business.industryResearch030208 emergency & critical care medicinemedicine.diseaseLogistic Modelslnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]Respiratory failureEmergency medicineObservational studybusiness
researchProduct

Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021

2021

COVID study groups - PORTUGAL: Portuguese Laboratory Network for the Diagnosis of COVID-19 and Public Health Department of the Health Administrative Regions, Physicians that provided data and samples from suspected cases and SARS-CoV-2 genetic characterization. INSA laboratory team for the diagnosis of SARS-CoV-2. Algarve Biomedical Center and Unilabs. We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0-2.9; B.1.351: 3.6, 95…

Infecções Respiratórias2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Critical CareEpidemiologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)variants of concernSettore MED/42 - Igiene Generale E Applicata03 medical and health sciences0302 clinical medicineVirologyInternal medicineMedicineHumansIntensive care admission030212 general & internal medicineCOVID-19; Europe; SARS-CoV-2; surveillance; variants of concern; Critical Care; Europe; Humans; COVID-19; SARS-CoV-2Surveillancebusiness.industrySARS-CoV-2030503 health policy & servicesPublic Health Environmental and Occupational HealthCOVID-19Odds ratioConfidence intervalEuropesurveillanceVariants of ConcernCOVID-19 Europe SARS-CoV-2 surveillance variants of concern0305 other medical sciencebusinessRapid CommunicationHuman
researchProduct

Co-circulation of the two influenza B lineages during 13 consecutive influenza surveillance seasons in Italy, 2004-2017

2019

AbstractBackgroundSince 1985, two antigenically distinct lineages of influenza B viruses (Victoria-like and Yamagata-like) have circulated globally. Trivalent seasonal influenza vaccines contain two circulating influenza A strains but a single B strain and thus provide limited immunity against circulating B strains of the lineage not included in the vaccine. In this study, we describe the characteristics of influenza B viruses that caused respiratory illness in the population in Italy over 13 consecutive seasons of virological surveillance, and the match between the predominant influenza B lineage and the vaccine B lineage, in each season.MethodsFrom 2004 to 2017, 26,886 laboratory-confirme…

0301 basic medicineInfluenza virological surveillance Influenza B virus Victoria lineage Yamagata lineage Vaccine matchmedicine.medical_specialtyLineage (evolution)PopulationInfluenza B viruHemagglutinin (influenza)Vaccine matchSettore MED/42 - Igiene Generale E ApplicataViruslcsh:Infectious and parasitic diseases03 medical and health sciences0302 clinical medicineMedical microbiologyImmunityRetrospective StudieInfluenza HumanmedicineHumanslcsh:RC109-216030212 general & internal medicineeducationPhylogenyRetrospective Studieseducation.field_of_studybiologyStrain (biology)Victoria lineageInfluenza B virus; Influenza virological surveillance; Italy; Vaccine match; Victoria lineage; Yamagata lineageVirologyInfluenzaInfluenza B virus030104 developmental biologyInfectious DiseasesInfluenza virological surveillanceParasitologyItalyInfluenza VaccinesInfluenza virological surveillance Influenza B virus Victoria lineage Yamagata lineage Vaccine match ItalyEpidemiological Monitoringbiology.proteinInfluenza B virus; Influenza virological surveillance; Italy; Vaccine match; Victoria lineage; Yamagata lineage; Epidemiological Monitoring; Humans; Influenza B virus; Influenza Vaccines; Influenza Human; Italy; Phylogeny; Retrospective Studies; SeasonsSeasonsInfluenza VaccineYamagata lineageResearch ArticleHuman
researchProduct

SIUMB recommendations for focal pancreatic lesions

2020

AbstractContrast-enhanced ultrasonography (CEUS) is increasingly being performed in Italy and Europe, particularly in the field of hepato-gastroenterology. Initially, it was mainly carried out to characterize focal hepatic lesions, but, since then, numerous studies have demonstrated its efficacy in the differential diagnosis of focal pancreatic pathologies (D’Onofrio et al. in Expert Rev Med Devices 7(2):257–273, 2010; Vidili et al. in J Ultrasound 22(1):41–51, 2019). The purpose of this paper is to provide Italian Medical Doctors with recommendations and thereby practical guidelines on the management of these patients. The present paper reports the final conclusions reached by the SIUMB gu…

Image-Guided Biopsymedicine.medical_specialtyPercutaneousContrast Media030218 nuclear medicine & medical imagingDiagnosis Differential03 medical and health sciencesPancreatic cystic lesion0302 clinical medicinePancreatic cancerCEUS; Contrast-enhanced ultrasound; Pancreas; Pancreatic adenocarcinoma; Pancreatic biopsy; Pancreatic cancer; Pancreatic cancer; Pancreatic cystic lesions; Ultrasound; Diagnosis Differential; Humans; Image-Guided Biopsy; Pancreatic Cyst; Pancreatic Neoplasms; Ultrasonography; Contrast MediaDiagnosisCEUS Ultrasound Contrast-enhanced ultrasound Pancreas Pancreatic adenocarcinoma Pancreatic cystic lesions Pancreatic biopsy Pancreatic cancerUltrasoundInternal MedicinemedicineHumansPancreaRadiology Nuclear Medicine and imagingPancreatic biopsyPancreasCEUS; Contrast-enhanced ultrasound; Pancreas; Pancreatic adenocarcinoma; Pancreatic biopsy; Pancreatic cancer; Pancreatic cancer; Pancreatic cystic lesions; UltrasoundUltrasonography030219 obstetrics & reproductive medicinebusiness.industryGeneral surgeryPancreatic biopsyGeneral MedicineGuidelinePancreatic cancermedicine.diseasePancreatic Neoplasmsmedicine.anatomical_structureDifferentialCEUSOriginal ArticleCEUS; Contrast-enhanced ultrasound; Pancreas; Pancreatic adenocarcinoma; Pancreatic biopsy; Pancreatic cancer; Pancreatic cystic lesions; UltrasoundUltrasonographyDifferential diagnosisPancreatic CystbusinessPancreasPancreatic adenocarcinomaContrast-enhanced ultrasoundContrast-enhanced ultrasoundPancreatic cystic lesions
researchProduct